Evidence map›Paper›PMID 22806961›Full record

ArticleHuman brain mapping2013

Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease.

Meredith N Braskie, Luis D Medina, Yaneth Rodriguez-Agudelo, Daniel H Geschwind, Miguel Angel Macias-Islas, Paul M Thompson, Jeffrey L Cummings, Susan Y Bookheimer, John M Ringman

Open access · greenAbstract read
In one paragraph

Article in Human brain mapping, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Frontiers in aging neuroscience · 2022
    Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Meredith N BraskieMary S. Easton Center for Alzheimer's Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California; Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California; Laboratory of Neuro Imaging, David Geffen School of Medicine at UCLA, Los Angeles, California.
Luis D Medina
Yaneth Rodriguez-Agudelo
Daniel H Geschwind
Miguel Angel Macias-Islas
Paul M Thompson
Jeffrey L Cummings
Susan Y Bookheimer
John M Ringman
University of California, Los Angeles · USFoundation for Psychocultural Research · USInstituto Nacional de Neurología y Neurocirugía · MXUniversidad de Guadalajara · MX

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASHINGTON, ARNOLD E. · 1985 to 2011
$43.4M
UCLA ALZHEIMERS DISEASE RESEARCH CENTERP50AG016570 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BREDESEN, DALE E. · 1999 to 2014
$25.9M
Alzheimer's disease risk analyzed using population imaging genomicsR01AG040060 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2011 to 2016
$2.5M
FMRI in Pre-Symptomatic PS1-related Alzheimer's DiseaseK08AG022228 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RINGMAN, JOHN M · 2003 to 2005
$481k
NCATS NIH HHS UL1 TR000124NCRR NIH HHS M01 RR000865NIA NIH HHS K08 AG022228NIA NIH HHS P50 AG016570NIA NIH HHS R01 AG040060
6 · The paper itself

Abstract

Rare autosomal dominant mutations result in familial Alzheimer's disease (FAD) with a relatively consistent age of onset within families. This provides an estimate of years until disease onset (relative age) in mutation carriers. Increased AD risk has been associated with differences in functional magnetic resonance imaging (fMRI) activity during memory tasks, but most of these studies have focused on possession of apolipoprotein E allele 4 (APOE4), a risk factor, but not causative variant, of late-onset AD. Evaluation of fMRI activity in presymptomatic FAD mutation carriers versus noncarriers provides insight into preclinical changes in those who will certainly develop AD in a prescribed period of time. Adults from FAD mutation-carrying families (nine mutation carriers, eight noncarriers) underwent fMRI scanning while performing a memory task. We examined fMRI signal differences between carriers and noncarriers, and how signal related to fMRI task performance within mutation status group, controlling for relative age and education. Mutation noncarriers had greater retrieval period activity than carriers in several AD-relevant regions, including the left hippocampus. Better performing noncarriers showed greater encoding period activity including in the parahippocampal gyrus. Poorer performing carriers showed greater retrieval period signal, including in the frontal and temporal lobes, suggesting underlying pathological processes.

Indexed as

Brain MappingAdultAlzheimer DiseaseAmyloid beta-Protein PrecursorBrainFemaleHumansImage Processing, Computer-AssistedMaleMemory DisordersMental RecallMiddle AgedMutationOxygenPaired-Associate LearningPresenilin-1Amyloid beta-Protein PrecursorOxygenPresenilin-1PSEN1 protein, humanAPPearly onsetfunctional magnetic resonance imaginghippocampusmedial temporal lobemutationPSEN1volume

Identifiers

PMID22806961
PMCPMC3812259
OpenAlexW1936067772

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.